A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

Inclusion Criteria: * Given written informed consent * Aged 19 - 65 years * Expected liver transplantation related to hepatitis B * Positive HBsAg Exclusion Criteria: * Patients has participated in any other clinical trial within 30 days * Patients who are scheduled re-operation for liver transplantation * Patients with are co-infected with HAV, HCV or HIV * History of malignant tumor within 5 years except primary liver cancer * Patients with moderate or severe renal disorder (serum creatinine \> 1.5 X ULM) or anuria, acute renal failure or dialysis * Patients who had experienced cardiovascular attack, myocardiac infarction, PTCA or coronary bypass or with angina, arrhythmia, or any other clinically meaningful valvular heart disease, cerebral infarction or cerebral hemorrhage within 6 months * History of anaphylaxis against active ingredient or excipients of study drug * Patients who had been vaccinated with parenteral live vaccine (measles vaccine, epidemic parotitis vaccine, rubella vaccine, cholera vaccine, chickenpox vaccine) within 3 months * Patients who had been treated with any other immuno globulin within 3 months * Pregnant or breast-feeding women * Women of childbearing potential who do not agree to use appropriate contraceptive methods (condom, an intrauterine device, oral contraceptive hormones, or a vasectomy of male sex partner) during this study * Alcohol or drug abuse within 6 months * Patients who has any clinically meaningful disease in investigator's judgement to prevent participating in this study